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THE OFFICE OF RESEARCH INTEGRITY:
EXPERIENCE AND AUTHORITIES
ChrisB. Pascal*

I.

INTRODUCTION

The Office of Research Integrity ("ORI") is a statutory office
created by Congress in 1993,' for which authority to respond to
allegations of "misconduct in science" originally arose under an earlier
federal regulation.2 Under the 1993 legislation, the key requirements for
ORI are: responding to allegations of research misconduct, defining
research misconduct, and overseeing inquiries and investigations of
research misconduct initiated by research institutions that receive Public
Health Service ("PHS") funds or apply for such funds.3 In addition, the
statute specifically requires ORI to establish administrative processes
and standards for protecting whistleblowers who act in "good faith.A
ORI has implemented the requirement to protect whistleblowers,
using the term "complainants" in the regulation, by adding specific
requirements to the "Public Health Service Policies on Research
Misconduct" ("PHS regulation"), promulgated May 17, 2005.' In
* B.A., Auburn University (1971); J.D., Duke University of Law (1974). The opinions
expressed herein are those of the author and do not necessarily represent the views of the Office of
Research Integrity, the U.S. Department of Health and Human Services, or any other federal
agency.
1. National Institutes of Health Revitalization Act of 1993, Pub. L. No. 103-43, § 161, 107
Stat. 122, 140-41 (codified as amended at 42 U.S.C. § 289b (2000)).
2. Responsibility of PHS Awardee and Applicant Institutions for Dealing with and Reporting
Possible Misconduct in Science, 54 Fed. Reg. 32,449 (Aug. 8, 1989) (codified at 42 C.F.R.
§§ 50.101-.105 (2004)). In 2005, the Department of Health and Human Services promulgated a final
rule removing 42 C.F.R. pt. 50, with the authority and functions of the ORI relocated to "a new
more comprehensive part" at 42 C.F.R. pt. 93. Public Health Policies on Research Misconduct, 70
Fed. Reg. 28,370, 28,370, 28,384-85 (May 17, 2005) (codified at 42 C.F.R. §§ 93.400-.413 (2007)).
3. 42 U.S.C. § 289b(a)(3)(A), (c).
4. Id. § 289b(e).
5. See, e.g., 42 C.F.R. § 93.108 (limiting the "disclosure of the identity of respondents and
complainants in research misconduct proceedings").
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§ 93.210 of the PHS regulation, ORI has defined "good faith" in
reporting allegations of research misconduct "as applied to a
complainant or witness" to mean "having a belief in the truth of one's
allegation or testimony that a reasonable person in the complainant's or
witness's position could have based6 on the information known to the
complainant or witness at the time."
In addition, the PHS regulation imposes responsibilities on research
institutions to protect good faith complainants, witnesses and committee
members who participate in conducting inquiries and investigations of
misconduct. Under § 93.300(d), the institution is required to "[t]ake all
reasonable and practical steps to protect the positions and reputations of
good faith complainants, witnesses and committee members and protect
them from retaliation by respondents and other institutional members."7
Moreover, § 93.300(e) requires institutions to provide confidentiality "to
all respondents, complainants, and research subjects identifiable from
research records or evidence." 8 This requirement for confidentiality is
critical to a fair and competent process for respondents, complainants,
and other involved parties. Without protections for confidentiality, the
complainant would be at increased risk of retaliation and the
respondent's reputation for honesty would be seriously jeopardized even
if the allegation was disproved. Both of these outcomes would
undermine the trust and fairness of the process.
II.

RESEARCH MISCONDUCT:

A.

A PRELIMINARY OVERVIEW

Defining Research Misconduct

In the PHS regulation, research misconduct is defined as:
fabrication, falsification, or plagiarism in proposing, performing, or
reviewing research, or in reporting research results.
(a) Fabrication is making up data or results and recording or reporting
them.
(b) Falsification is manipulating research materials, equipment, or
processes, or changing or omitting data or results such that the
research is not accurately represented in the research record.
(c) Plagiarism is the appropriation of another person's ideas,
processes, results, or words without giving appropriate credit.

6. 42 C.F.R. § 93.210.
7. Id. § 93.300(d).
8. Id. § 93.300(e).
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(d) Research misconduct
does not include honest error or differences
9
of opinion.
In order to make a finding of research misconduct, the institution or
ORI must find that there was a "significant departure from accepted
practices of the relevant research community;" that the misconduct was
"committed intentionally, knowingly, or recklessly;" and that "[t]he
allegation [was] proven by a preponderance of the evidence."' 0 The
institution or ORI has the burden of proof for finding research
misconduct." While honest error or honest difference of opinion can
negate a finding of research misconduct, the "respondent has the burden
of going forward with and proving, by a preponderance of the
evidence,"
2
that honest error or honest difference of opinion occurred.'
B. Limits to OR! Jurisdiction
In addition to the formal research misconduct contemplated under
the PHS regulation, there are a number of other questionable or irregular
research practices that diminish the accuracy and reliability of the
research processes and outcomes. These include bias in interpreting and
reporting research data, such as dropping data points without a
legitimate scientific justification, inadequate recordkeeping, failure to
report data that contradicts one's own research, and publishing the same
data multiple times that may mislead others into believing that the
significance of the data is greater than deserved. These actions would not
constitute research misconduct under the PHS regulation unless the
action was intentional, knowing, or reckless and, therefore, constituted
fabrication or falsification.
Bias can also occur when the "best" experiment is published rather
than a representative result. Similarly, biased reporting occurs when a
clinical trial is carried out with inadequate statistical power and it is
reported that the experimental treatment was unsuccessful. In fact, if
additional subjects were used in the study, the statistical power would be
greater and might demonstrate that the experimental treatment was
actually successful.
ORI jurisdiction is limited to allegations of misconduct where the
research is supported by PHS funds or there is an application for PHS

9.
10.
11.
12.

Id. § 93.103.
Id. § 93.104.
Id. § 93.106(b)(1).
Id. § 93.106(b)(2)-(3).
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funds. 13 In contrast, research institutions have no such limitation. For
example, if Johns Hopkins School of Medicine received an allegation of
misconduct against a Principal Investigator ("PI"), who was supported
by private funds, state funds, or a grant from a non-federal source, it
would have plenary authority to investigate and take actions against the
PI under its own authority as employer and manager of the research
institution, assuming that it has the appropriate institutional policies in
place, 14 which many large institutions do.
ORI has no jurisdiction over misconduct allegations that involve
private funding, state funding, or other sources such as a foundation or a
non-profit that supports research.' 5 ORI also does not have misconduct
jurisdiction over falsification or fabrication of research that involves the
regulatory authority of the Food and Drug Administration, such as new
drug applications. 6 However, there are misconduct cases where there
could be joint jurisdiction by ORI and the FDA, such as when there is
both PHS funding and FDA regulatory authority over a pending new
drug application where misconduct is alleged. In addition, ORI has
jurisdiction over research misconduct that is alleged in the FDA
intramural research program since that research is supported with PHS
funds. 17
C. Federal-widePolicy on Research Misconduct
The Department of Health and Human Services ("HHS"), acting
through ORI, is not the only entity that responds to research misconduct.
In 2000, under the auspices of the White House Office of Science and
Technology Policy ("OSTP"), a federal-wide policy on research
misconduct was adopted following a Federal Register announcement,
receipt of public comments, and final publication of the federal-wide
policy.' 8 The general framework for federal agency management of
research misconduct was the result of this process. Approximately
sixteen science agencies were involved in the OSTP process, including
HHS, the National Science Foundation ("NSF"), the Department of

13. Id. § 93.102(a).
14. Id. § 93.319; see Office of Research Integrity, Handling Misconduct-Inquiry Issues,
http://ori.dhhs.gov/misconduct/inquiryissues.shtml (last visited Feb. 22, 2007).
15. See id.
16. See id.
17. Id.
18. Federal Policy on Research Misconduct, 65 Fed. Reg. 76,260, 76,260-64 (Dec. 6, 2000).
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Veteran Affairs, the Department of Energy, and many others. 9 HHS
(through ORI) and NSF are by far the most active federal agencies in
responding to allegations and making findings of research misconduct.2 °
ORI has made over 160 confirmed findings of misconduct since 1992
and averages approximately thirteen findings a year. 21
III.

ADDITIONAL AUTHORITIES DELEGATED TO ORI

ORI has been delegated additional authority to promote research
integrity and prevent research misconduct through education and
training in the responsible conduct of research, activities designed to
promote research integrity and prevent research misconduct, and
research and evaluation programs.2 2 Under this additional authority, ORI
has been very active in sponsoring workshops and conferences related to
research misconduct, research integrity, and education in the responsible
conduct of research.23
A.

Maintainingthe Responsible Conduct of Research Program

Since the year 2000, ORI has invested hundreds of thousands of
dollars in promoting responsible research practices in the research
community. 24 A workshop and conference program provided a platform
for individual research institutions and scientific associations to discuss
scientific topics such as research misconduct, authorship responsibilities,
mentoring, protection of human subjects, clinical research, standards of
conduct within specific scientific disciplines, new emerging issues, such
as the importance of financial conflicts of interest, and other topics
19. See Office of Research Integrity, Policies-Federal
policies/federal-policies.shtml (last visited Feb. 22, 2007).

Policies,

http://ori.dhhs.gov/

20. See COUNCIL ON GOVERNMENTAL RELATIONS, ACCESS TO AND RETENTION OF
RESEARCH
DATA:
RIGHTS
AND
RESPONSIBILITIES
19
(2006),
available at

http://206.151.87.67/docs/CompleteDataRetentionBooklet.doc.
21. LAWRENCE J. RHOADES, ORI CLOSED INVESTIGATIONS INTO MISCONDUCT ALLEGATIONS
INVOLVING RESEARCH SUPPORTED BY THE PUBLIC HEALTH SERVICE: 1994-2003, at 6 (2004); Chris

B. Pascal, Director of ORI, The Role of HHS Office of Research Integrity in Investigating Research
Misconduct, Statement Before the Subcommittee on Criminal Justice, Drug Policy and Human
Resources Committee on Government Reform (Mar. 7, 2006).
22. Statement of Organization, Functions, and Delegations of Authority, 65 Fed. Reg. 30,600,
30,600-01 (May 12, 2000).
23. See, e.g., Office
of Research Integrity,
Conferences-Past
Conferences,
http://ori.dhhs.gov/conferences/past.conf.shtml (last visited Feb. 22, 2007).
24. See, e.g., ORI, ANNUAL REPORT 2005, at 19, available at http://ori.dhhs.gov/
documents/annual reports/ori annual report_2005.pdf (observing that the ORI awarded a total of
$225,000 for the creation of "Internet-based assessment and instructional materials on peer review,
data management, mentoring, and laboratory management" in 2005).
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important to the scientific community and individual scientific
disciplines.25
ORI also developed the Responsible Conduct of Research ("RCR")
program, a resource development program that provides funding to
research institutions and others to produce educational programs and
tools that could be used to educate scientists and institutions on a variety
of topics. The RCR resource program has made fifty awards, with thirty
projects completed and posted on the ORI website for use by national
and international scientists and research institutions. 26 ORI has also
funded discrete products in house, such as the "ORI Introduction to the
Responsible Conduct of Research," which has sold thousands of copies
and been translated into Chinese, Japanese and Korean.27 This booklet
covers the nine key elements of responsible research, including research
misconduct, the protection of human subjects, the welfare of laboratory
animals, conflicts of interest, data management practices, mentoring and
trainee responsibilities, collaborative research, authorship and
publication, and peer review.28
ORI also funded, in collaboration with the American Association of
Medical Colleges ("AAMC"), research integrity activities by scientific
societies and associations. This project lasted for four years and funded
thirty-nine awards to thirty-three academic societies.29 Many societies
held conferences and workshops and developed specific products on
topics such as conflict of interest and education in the responsible
conduct of research.
ORI has also contracted with the University of Miami,
Collaborative Institutional Training Initiative ("CITI") program to
develop a web-based RCR education program that would be available
worldwide for researchers, administrators, students, post-docs and

25. See generally NICHOLAS H. STENECK, ASSESSING THE INTEGRITY OF PUBLICLY FUNDED
RESEARCH: A BACKGROUND REPORT FOR THE NOVEMBER 2000 ORI RESEARCH CONFERENCE ON
RESEARCH INTEGRITY (2000).
Program,
26. See Office of Research
Integrity, RCR-Research
Development
http://ori.dhhs.gov/education/rcrrdp/ (last visited Feb. 22, 2007).
http://ori.dhhs.gov/
27. See Office of Research Integrity, International-Activity,
intemational/activity/KoreansGetORIText.shtml (last visited Feb 22, 2007); OR] Intro to RCR
Availablefor Fall,ORI NEWSL. (ORI/U.S. Dep't of Health & Human Servs., Rockville, Md.), Mar.
2006, at 3, availableat http://ori.hhs.gov/publications/documents/Mar06ORNewsletter.pdf.
28. See NICHOLAS H. STENECK, ORI INTRODUCTION TO THE RESPONSIBLE CONDUCT OF

RESEARCH, at vii-ix (2004).
29. See Office
of Research
Integrity, AAMC Funded Projects
http://ori.hhs.gov/education/aamc-funded_l-3.shtml (last visited Feb. 22, 2007).
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others.30 This program will be provided to users free of charge and, once
operational, should increase RCR education training to thousands of
additional scientists, research administrators and other interested
parties. 3'
B. Assuring the Integrity of the Scientific Literature
ORI believes it is important to the research community, individual
scientists, and the public to correct or retract scientific articles that are
falsified, fabricated, or simply incorrect. Between 1992 and 2006, ORI
corrected or retracted 138 articles.32 ORI cannot do this acting alone, but
relies on the appropriate journals to cooperate in correcting the
literature.33 Most journals have been very helpful in that regard.
Sometimes journals become aware of false or incorrect articles and
retract or correct them on their own accord, before ORI has completed
its actions in a specific case.
In addition, many institutions will correct or retract articles when
they become aware of a problem with a published article. The need to
take action may become evident when an allegation of misconduct is
made at the institution or the PI reviews a manuscript or published
article and realizes that the data does not support the findings and
conclusions in the paper.
ORI will take action to correct the literature in response to a finding
of research misconduct when it concludes that an article is falsified or
fabricated.34 ORI will take steps to impose an administrative action,
which requires the scientist to make corrections or retractions to the
article consistent with the findings of misconduct. 35 This is often
implemented through a voluntary exclusion agreement that requires the
scientist to submit a letter to the appropriate journal asking for the
retraction or correction, consistent with the terms of the written
agreement.36 In two recent ORI cases, which have been made public and
30.

See Paul Braunschweiger, CITI RCR Course Offers Customized Instruction, ORI NEWSL.

(ORI/U.S. Dep't of Health & Human Servs., Rockville, Md.), Dec. 2006, at 1, available at
http://ori.dhhs.gov/publications/documents/Dec06-ORI-Newsletter.pdf.
31. See id.
32. ORI, U.S. DEP'T OF HEALTH & HUMAN SERVS., MANAGING ALLEGATIONS OF SCIENTIFIC
MISCONDUCT: A GUIDANCE DOCUMENT FOR EDITORS 4 (2000) [hereinafter GUIDANCE
DOCUMENT].
33. See id. at 9.
34. See 42 C.F.R. § 93.103.
35. Id. § 93.407(a)(I).
36. See, e.g., Notice on Findings of Scientific Misconduct, 70 Fed. Reg. 15,092, 15,095 (Mar.
24, 2005).
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are posted on the ORI website, many articles were retracted and
corrected as part of the administrative actions taken against the accused
scientist.
In the case of Eric Poehlman, a scientist previously employed by
the University of Vermont ("UVM"), ORI required and Dr. Poehlman
agreed, to ten retractions and corrections of the literature as part of the
settlement of ORI's misconduct findings against the investigator.37 This
case also included criminal and civil actions against Dr. Poehlman based
on actions taken by the United States Attorney's Office in Vermont and
by the HHS Office of Inspector General. ORI staff participated in
reviewing the UVM investigation report and made twenty additional
research misconduct findings based on ORI analysis of the research
data.38 The Poehlman case is a good example of how ORI participates in
civil and criminal investigations conducted by the United States
Attorney's Office and the HHS Office of Inspector General. Dr.
Poehlman was sentenced to jail time for one year and one day and paid
the federal government $180,000 as a civil fraud fine due to the
extensive fraud.3 9
In another recent case involving Dr. Leadon from the University of
North Carolina, Chapel Hill, several articles were retracted and corrected
based on an ORI settlement agreement with Dr. Leadon. Additional
articles were separately retracted based on decisions made by the
relevant scientific journals. 40
C. JournalPoliciesthat Can FacilitateResponding
to Possible Research Misconduct
In 2000, ORI published Managing Allegations of Scientific
Misconduct: A GuidanceDocument ("Guidance Document"). 4 1 It states:
[Journal] editors have a responsibility to pursue possible scientific
misconduct in manuscripts submitted to or published in their journals
and to publish a retraction of any fraudulent paper published in their
journals. However, editors are not responsible for conducting a full
37. Press Release, Office of Research Integrity, Dr. Eric T. Poehlman (Mar. 17, 2005),
available at http://ori.dhhs.gov/misconduct/cases/press release-poehlman.shtml.
38. See Susan R. Morrissey, Research Misconduct, CHEMICAL & ENGINEERING NEWS, Nov.
6, 2006, at 18, 22, availableat http://pubs.acs.org/cen/govemment/84/8445govI.html.
39. See Press Release, Office of Research Integrity, Dr. Eric T. Poehlman (Mar. 17, 2005),
availableat http://ori.dhhs.gov/misconduct/cases/pressrelease-poehlman.shtml.
40. See Notice on Findings of Scientific Misconduct, 71 Fed. Reg. 33,308, 33,308-09 (June 8,
2006).
41.

See GUIDANCE DOCUMENT, supra note 32.
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investigation or deciding whether scientific misconduct occurred.
Those responsibilities rest with the institution where the work was
conducted or with the funding agency.42
In order to assist journal editors in meeting this responsibility, ORI
suggests that journals adopt clear, specific policies that inform all
authors who submit a manuscript that as a condition of submission, the
authors must agree to permit the journal to refer any manuscript that the
journal, in its sole discretion, determines is a suspicious manuscript and
warrants submitting the manuscript to the submitting institution or
funding agency for review, investigation, or other appropriate action.4 3
Journal policy should also state that the journal is relieved of any
liability 44due to wrongful action taken by the institution or funding
agency.
The Guidance Document further states:
The Council of Biology Editors [now named the "Council of Science
Editors"], a professional association of editors of many of the world's
leading biomedical journals, has examined this issue and its Editorial
Policy Board recently drafted language for the purpose of aiding
journals with this task. The policy statement reads:
Should possible scientific misconduct or dishonesty in
research submitted for review by the journal be suspected or
alleged, the journal reserves the right to forward any submitted
manuscript to the sponsoring or funding institution or other
appropriate authority for investigation. The journal recognizes
the responsibility to ensure that the question is appropriately
actual investigation or
pursued, but does not undertake the
45
make determinations of misconduct.
D.

PublishingOR! Research Misconduct Cases

Although ORI believes strongly that confidentiality must be
respected when an individual is accused of research misconduct, it also
believes that misconduct must be publicly reported when it is
confirmed.4 6 Public reporting of research misconduct informs the public

42. Id. at 3.
43. See id. at 10.
44.

See id.

45. Id. (quoting Personal Communication from Council of Biology Editors, Chair of Editorial
Policy Board to ORI (July 1998)).
46. See 42 C.F.R. § 93.108.
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of real or potential harm when the misconduct is serious and may affect
clinical research or clinical trials. Furthermore, it prevents scientists
from going underground and ending up at a new institution where the
scientist can once again have an opportunity to commit misconduct.
When journal articles are fraudulent, public exposure provides the
opportunity to correct the scientific literature and to notify other
scientists working in the same field that there are fraudulent articles
upon which they cannot rely. Finally, publicity has a potential deterrent
effect. As other researchers learn about real cases of research
misconduct that may end a scientist's career, those who might be
tempted may think twice about the risks of committing research
misconduct.
Publicity can also have an educational component. By hearing
about real cases of misconduct, other scientists will realize that
misconduct is possible and may be more attentive to some of the
weaknesses in scientific research. This could broaden their
understanding of the way in which research is actually conducted and
encourage some investigators to focus on doing only high quality and
ethical research even when it appears to slow down scientific progress.
Engaging in high quality research all the time may, in fact, be the most
efficient and cost effective way to conduct research and produce
important new discoveries.
E. ORI AssuranceProgram
Consistent with the PHS regulation, ORI requires all PHS-funded
institutions to report annually the number of allegations received and
inquiries and investigations conducted on research misconduct.47
Institutions must file an annual report to maintain their assurance, a
requirement for them to apply for and receive PHS research funds. 48 The
institutions must also certify that they have an institutional policy on
research misconduct that is consistent with the regulation.4 9 In order to
facilitate quality institutional policies, ORI has developed a model policy
for research misconduct that is consistent with the PHS regulation. This
model policy was posted on the ORI website in November 2006 for
comment by research institutions. 50 The comment period was sixty
47. See id. § 93.302(b).
48. Id. § 93.301.
49. Id. § 93.304.
50. Office of Research Integrity, Policies: ORI Model Policy for Responding to Allegations of
Scientific Misconduct, http://web.archive.org/web/20060519180130/http://ori.dhhs.gov/documents/
model-policy-responding-allegations.pdf (last visited Feb. 22, 2007).
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days. 51 Following the comment period, ORI is considering some
additional edits to the model policy before posting the policy on the ORI
website 2
policy.5 3
Institutions, however, are not required to adopt the model
They may pick and choose those parts of the model policy that they find
helpful and ignore the rest, so long as the institutional policy is
consistent with the regulation. 4 ORI has suggested several optional
policies that may prove beneficial to the institution.
Below are a few examples of these optional policies that institutions
may find helpful.
1. Adopt Additional Standards
Under 42 C.F.R. § 93.319, institutions may adopt additional
standards of conduct that go beyond the PHS standards in Part 93. These
standards may be included in the same policy document as the PHS
standards. The additional standards will apply only to the internal
activities of the institution.
The University of Maryland, Baltimore, has adopted the following
policies at the institution, regarding misconduct in scholarly
additional
55
work:
1. It should be emphasized that reporting misconduct in scholarly
work is a responsibility shared by everyone at the institution.
However, frivolous, mischievous or malicious misrepresentation in
alleging misconduct will not be tolerated.
2. Misconduct in scholarly work may take many forms; these
guidelines apply, but are not limited to, the following examples of
misconduct:
1. Falsification of data. Ranging from fabrication to deceptively
selective reporting, including the purposeful omission of
conflicting data with the intent to falsify results.
For example,
manipulation.
2. Improper experimental
data.
biased
obtain
to
experiments
manipulating
51.

See ORIAsks for Comments on Research Misconduct Policy, BiORESEARCH COMPLIANCE

6
REP., Nov. 8, 2006, http://www.fdainfo.com/bicoonlinepages/BiCoOnlinell080 .htm (online
update page) [hereinafter ORI Asks for Comments].
52. Office of Research Integrity, Policies: ORI Model Policy for Responding to Allegations of
Misconduct, http://ori.dhhs.gov/policies/documents/ModelPolicyrblfinal IOGCCCM
Scientific
Commentsrblrevdraftfinal 102006.pdf (last visited Feb. 22, 2007).
53. OR] Asks for Comments, supra note 51.
54. Id.
55. Univ. of Md., Bait., USM/UMB Policies and Procedures, http://cf.umaryland.edu/
hrpolicies/section3/t30l 10sa.html (last visited Feb. 22, 2007).
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3. Plagiarism. For example, taking credit for an exact copy or the
rewritten or rearranged work of another.
4. Improper assignment of credit. For example, insufficiently or
knowingly not citing the work of others, including associates
and students, or inadequately identifying the repetition of data
or material that appears in more than one publication.
5. Abuse of confidentiality. For example, improper use of
information gained by privileged access, such as information
obtained through service on peer review panels and editorial
boards.
6. Deliberate violation of regulations. For example, failure to
comply with regulations concerning the use of human subjects,
the care of animals, or health and safety of individuals and the
environment.
7. Misappropriation of funds or resources. For example, the
misuse of funds for personal gain....
3. Allegations of misconduct in scholarly work may come from
various sources within and without the institution. It is important
that allegations of misconduct be handled expeditiously and that no
serious allegations go unheeded. Consequently, each campus must
develop specific procedures that define how allegations will be
evaluated, what levels of administration will be involved, and what
actions will be taken as the result of evaluating an allegation of
misconduct.
4. No decisions regarding the seriousness of an allegation of
misconduct should be made by anyone whose personal or
professional interests may be involved. Thus, although an
allegation may first be reported to a collaborator, a co-worker, a coauthor, a faculty advisor, or a team leader, such a close associate
must report the allegation to a designated senior official for further
action.
5. The purpose of the evaluation of an allegation is to determine
whether there is or is not substantial basis to believe that scholarly
misconduct has occurred, and whether formal discharge
proceedings or other action
with respect to the individual's
56
employment is warranted.

56. Id. (cross-references omitted).
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2. Maintain Two Research Integrity Officers
The regulation requires a "research integrity officer" ("RIO") to
manage allegations of research misconduct.5 7 Some institutions have
more than one campus, such as a medical school and a graduate school.
Thus, the institution may find it to be more effective to have two ROs,
one for each campus.
3. Allow Complainant to Comment on Investigation
Under the new regulation, the complainant no longer has the right
to review and comment on the inquiry and investigation.58 However,
since the complainant is often the most knowledgeable person about the
alleged misconduct, the institution may find it helpful to get comments
from the complainant on the inquiry and investigation reports. Thus, as
an option, the institution may permit the complainant to review and
comment on the inquiry and investigation reports, subject to a written
agreement that the complainant will maintain the confidentiality of the
information obtained. This is required because the regulation protects the
confidentiality of the accused individual.
IV.

THE IMPORTANCE OF THE RESEARCH DATA: TOP TEN THINGS FOR
THE LAB CHIEF OR PI TO AVOID IN THE LABORATORY

ORI believes that the research data is the most important output of
the research process. However, for the data to be useful, it must be
accurate, based on the actual research records, and interpreted and
reported honestly. The tendency of some scientists to stretch the truth to
get published or funded undermines the trustworthiness of the science
and harms public confidence in the products and treatments that result
from the research enterprise. ORI encourages all players in the research
enterprise to promote the transparency and accuracy of the research
findings to the greatest extent possible.
The following is a list of the top ten things for the lab chief or PI to
avoid in the laboratory in order to maintain the integrity of research data:
1. Fail to review the raw data prior to publication; accept summary
data or prepared tables or graphs instead.
2. On a project where expected results have not been achieved over
several months, demand significant results immediately to meet a
57. See42 C.F.R. § 93.301(b).
58. See id. § 93.308(b); Office of Research Integrity, Policies-Regulations: Questions and
Answers--42 C.F.R. pt. 93, http://ori.hhs.gov/policies/QA-Reg-6-05.shtml (last visited Feb. 22,
2007).
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publication or grant deadline, which can dramatically increase
pressure on the staff to manipulate the data to support the desired
outcome.
3. Hire a new post-doc who comes highly recommended, but leave
him or her without guidance or supervision.
4. Tell your staff to do the right thing, but do the convenient thing
when it is expedient.
5. Publish the results of a team research project, but leave out one or
two members of the team who made substantive contributions and
met the criteria for authorship.
6. Provide no specific guidance or standards for keeping laboratory
data. Let each lab member choose his or her own technique for
handling data.
7. Tell your lab members to ask questions, but don't make yourself
available because you are too busy.
8. Have a large lab of junior scientists and provide little supervision
or guidance.
9. Drop data points in order to "clean up" your graph or table without
a clear scientific rationale that an outsider who understands the
experiment would consider legitimate.
10. Tell the lab tech what results you expect from the experiment and
that you need the results right away.
Many junior scientists will do their best to give the Lab Chief or PI
what he or she expects, even if the scientist has to make the data "fit" the
request. This is especially true, when the junior staff is in an insecure
position, such as a temporary position, receiving soft money, or on a
green card. A recent study indicates that many scientists deviate from
scientific norms of behavior, especially at major stress points, such as
submitting an article for publication or seeking grant support. 59 To
ensure that the research is correctly reported, the PI should review the
raw data carefully before publication and grant submission, involve the
junior staff as appropriate in discussing and interpreting the data, and set
expectations for lab staff on collecting and maintaining the data, so that
it is available to the PI and staff.
A recent ORI study found that about twenty-five percent of PIs did
not spend adequate time supervising staff, reviewing the data, and
otherwise managing the laboratory and training junior staff.60 This

59. See Brian C. Martinson et al., Scientists Behaving Badly, 435 NATURE 737, 737-38 & tbl.1
(2005).
60. See AM. INSTS. FOR RESEARCH, SURVEY OF RESEARCH INTEGRITY MEASURES UTILIZED
IN BIOMEDICAL RESEARCH LABORATORIES: FINAL REPORT 88, 41 exhibit 12 (2003), available at
http://ori.dhhs.gov/documents/research/intergity-measures-final-reportl l_07_03.pdf; Jim Giles,
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creates risks in the lab that the research may be sloppy, not reported
properly, and may encourage staff to commit research misconduct and
engage in questionable research practices that do not meet the norms of
good scientific behavior.
V.

A FEW LEGAL ISSUES RELEVANT TO INTEGRITY

A.

Confidentiality

ORI has a long history of providing confidentiality for individuals
who are accused of research misconduct. When ORI was officially
established in 1993, it became very clear to ORI and the research
community that confidentiality was a core requirement for accused
scientists to protect their reputations, until a determination of research
conduct was made, and beyond the proceedings if it was concluded that
actionable research did not occur. If the name of the accused individual
was released before a finding was made, there would always be a cloud
over the accused, even if he or she were subsequently exonerated. 61 This
principle of confidentiality has existed to this day and I believe the
science community regards it as a fundamental requirement for fairness
in the system for responding to allegations of misconduct.
This confidentiality requirement is codified in § 93.108 of the PHS
regulation, and mentioned numerous times in that regulation.
Additionally, only a small percentage of misconduct allegations made
against accused scientists result in misconduct findings. Thus,
confidentiality protection is critical to the process because it protects the
reputations of those scientists who have not committed misconduct.
Further, the federal Privacy Act 62 also applies to ORI research
misconduct records.63
Consistent with these principles, ORI neither admits nor denies any
specific matter when it receives a request for information regarding any
misconduct case, or suspected case of misconduct.64 In accordance with
HHS policy on federal document requests, ORI forwards such requests
to the Public Health Service Freedom of Information Act ("FOIA")
Breeding Cheats, 445 NATURE 242, 243 (2007), available at http://www.nature.com/
nature/joumal/v445/n7125/full/445242a.html#B5 (interpreting data from the report to conclude that
"one in four lab heads did not take their supervisory roles seriously enough").
61. See RESEARCH TRIANGLE INST., SURVEY OF ACCUSED BUT EXONERATED INDIVIDUALS IN
RESEARCH MISCONDUCT CASES: FINAL REPORT 86-87 (1996).
62. 5 U.S.C. § 552a (2000).
63. 42 C.F.R. § 93.414.
64. See id. § 93.108.
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Office for processing as a FOIA request. 65 In balancing these policy
considerations, courts agree. In McCutchen v. HHS, the United States
Court of Appeals for the District of Columbia ruled, in a decision under
the FOIA, that the privacy of accused scientists who had not been found
guilty of research misconduct outweighed the public interest in the
disclosure of the names of the accused.66
B.

InstitutionalLiability

After he was accused of scientific misconduct, Dr. Kimon
Angelides filed a civil suit in Texas state court against the Baylor
College of Medicine, and several of its employees who served on the
inquiry and investigation committees, for slander and other torts. 67 A
trial date was set, but before the trial was completed, the case was settled
and dismissed after the HHS Departmental Appeals Board upheld the
ORI findings of misconduct against Dr. Angelides.68
C. Protectionsfor Complainants Who Make Good Faith
Allegations of Research Misconduct
The PHS regulation states that the institution must "[t]ake all
reasonable and practical steps to protect the positions and reputations of
good faith complainants, witnesses and committee members and protect
them from retaliation by respondents and other institutional members. 69
To act in good faith, the complainant must have "a belief in the truth of
one's
allegation... that
a
reasonable
person
in
the
complainant's.., position could have based on the information known
to the complainant... at the time., 70 However, "[a]n allegation or
cooperation with a research misconduct proceeding is not in good faith if
made with knowing or reckless disregard for information that would
negate the allegation or testimony.

65. See, e.g., Office of Research Integrity, ORI Handbook, http://ori.hhs.gov/documents/
riojhandbook.pdf (last visited Feb. 22, 2007).
66. 30 F.3d 183, 188-89 (D.C. Cir. 1994).
67. See Angelides v. Baylor Coll. ofMed., 117 F.3d 833, 835 (5th Cir. 1997).
68. See Kimon J. Angelides, Dep't of Health & Human Servs. Appeals Bd., Decision No.
1677, at 1 (Feb. 5, 1999).
69. 42 C.F.R. § 93.300(d).
70. Id. § 93.210.
71. Id.
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D. Defamation and Breach of Confidentiality
Even if an allegation is made in good faith, it is important not to
make public disclosures about the allegation. If an allegation is not
proven and it is made public by the complainant, there is the possibility
that the complainant can be sued for defamation or invasion of privacy.
If there are concerns about how to report misconduct, the complainant
should be careful to seek advice from the institutional RIO or from ORI
before making an allegation.
In one such case, Dr. Gerald Rosen, a scientist at the University of
Maryland Baltimore, was accused of scientific misconduct by Dr.
Carmen Arroyo.72 Dr. Rosen sued Dr. Arroyo for defamation and
invasion of privacy and was awarded a jury verdict of about $75,000
which was upheld on appeal. The Maryland Court of Special Appeals
ruled that Dr. Arroyo did not have an absolute privilege to report her
allegations of misconduct. There was also evidence that Dr. Arroyo
repeated her allegations after the University of Maryland and the
Veteran's Administration concluded that Dr. Rosen had not committed
research misconduct.73 In addition, the court found evidence that Dr.
Arroyo further disclosed the allegation
to the Baltimore Sun, which
74
constituted an invasion of privacy.
E. IntentionalInterference with a Scientist'sResearch Project
In the case of United States v. Arora, a Maryland court ruled that
Dr. Prince Kumar Arora "undermined the honor system that exists
among the community of scientists, a system which is ultimately based
on 'truthfulness, both as a moral imperative and as a fundamental
operational principle in the scientific research process."'' 75 Dr. Arora
intentionally destroyed the cells of another scientist while conducting a
government research project. The court required Dr. Arora to pay
76
$450.20 in compensatory damages and $5000 in punitive damages.
This case demonstrates that even when formal research misconduct is
not found, a scientist who violates scientific norms can still be held
accountable on other grounds.

72. Arroyo v. Rosen, 648 A.2d 1074, 1075 (Md. Ct. Spec. App. 1994).
73. See id. at 1076, 1078.
74. Id. at 1080.
75. 860 F. Supp. 1091, 1101 (D. Md. 1994) (quoting PANEL OF SCIENTIFIC RESPONSIBILITY &
THE CONDUCT OF RESEARCH, COMM. ON Sci., ENG'G, & PUB. POLICY, NAT'L ACAD. OF SCIS.,
ENSURING THE INTEGRITY OF THE RESEARCH PROCESS 17 (1992)).

76. Id.
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InstitutionalAuthority to Take Action When ORI Declines

In Shovlin v. University of Medicine and Dentistry of New Jersey,
the court stated: "Even though the federal agency [ORI] to which the
university reported may not have considered duplicate publication to
constitute 'misconduct in science,' it recognized the University's right to
hold such a practice to be unacceptable."" In this case, the individual
had published the same paper twice, which violates most journal
policies. Journals, typically in the instructions to authors, specify that the
work must be original and not previously published.7 8 While ORI did not
consider duplicate publication (sometimes called self-plagiarism) to be
research misconduct under ORI's jurisdiction, it acknowledged that an
79
institution could do so under its own policies. The court concurred.
G.

ORI Policy on Plagiarism

Although there is widespread agreement in the scientific
community on including plagiarism as a major element of the PHS
definition of scientific misconduct, there is some uncertainty about
how the definition of plagiarism itself is applied in ORI cases.
As a general working definition, ORI considers plagiarism to
include both the theft or misappropriation of intellectual property and
the substantial unattributed textual copying of another's work. It does
not include authorship or credit disputes.
The theft or misappropriation of intellectual property includes the
unauthorized use of ideas or unique methods obtained by a privileged
communication, such as a grant or manuscript review.
Substantial unattributed textual copying of another's work means
the unattributed verbatim or nearly verbatim copying of sentences and
paragraphs which materially mislead the ordinary reader regarding the
contributions of the author. ORI generally does not pursue the limited
use of identical or nearly-identical phrases which describe a
commonly-used methodology or previous research because OR does
not consider such use as substantially misleading to the reader or of
great significance.
77. 50 F. Supp. 2d 297, 314 (D.N.J. 1988).
78. See, e.g., International Committee of Medical Journal Editors, Uniform Requirements for
Manuscripts Submitted to Biomedical Journals, http://www.icmje.org (last visited Feb. 22, 2007)
(stating that upon finding of a redundant or duplicate manuscript, "prompt rejection of the submitted
manuscript should be expected" by the author); Journal of Abnormal Psychology, Instructions to
Authors, http://www.apa.org/journals/abn/submission.html (last visited Feb. 22, 2007) (proscribing
the "publication of any manuscript that has already been published in whole or substantial part
elsewhere").
79. See Shovlin, 50 F. Supp. 2d at 318.
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Many allegations of plagiarism involve disputes among former
collaborators who participated jointly in the development or conduct of
a research project, but who subsequently went their separate ways and
made independent use of the jointly developed concepts, methods,
descriptive language, or other product of the joint effort. The
ownership of the intellectual property in many such situations is
seldom clear, and the collaborative history among the scientists often
supports a presumption of implied consent to use the products of the
collaboration by any of the former collaborators.
For this reason, ORI considers many such disputes to be authorship
or credit disputes rather than plagiarism. Such disputes 8are referred to
PHS agencies and extramural institutions for resolution. 0
VI.

CONCLUSION

ORI's primary responsibilities in research misconduct and research
integrity include establishing regulations to provide a framework for
action by research institutions that receive PHS funds, providing
leadership in promoting positive actions in research institutions and the
scientific community to promote the responsible conduct of research,
encouraging good data practices, and other activities to improve the
research enterprise.
This cannot be accomplished without the support, collaboration,
and tireless efforts of many scientific societies and associations, research
institutions, and individual scientists and members of the public. We
should acknowledge with great gratitude their inspiration, good will, and
wise advice over many years.

80. ORI Provides Working Definition of Plagiarism,ORI NEWSL. (ORI/U.S. Dep't of Health
& Human Servs., Rockville, Md.), Dec. 1994, at 5-6.
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